Characterization of Mucosal Immune Responses to Enterotoxigenic Escherichia coli Vaccine Antigens in a Human Challenge Model: Response Profiles after Primary Infection and Homologous Rechallenge with Strain H10407

Enterotoxigenic Escherichia coli (ETEC) bacteria are the most common bacterial cause of diarrhea in children in resource-poor settings as well as in travelers. Although there are several approaches to develop an effective vaccine for ETEC, no licensed vaccines are currently available. A significant...

Full description

Saved in:
Bibliographic Details
Published inClinical and vaccine immunology Vol. 23; no. 1; pp. 55 - 64
Main Authors Chakraborty, Subhra, Harro, Clayton, DeNearing, Barbara, Ram, Malathi, Feller, Andrea, Cage, Alicia, Bauers, Nicole, Bourgeois, A. Louis, Walker, Richard, Sack, David A.
Format Journal Article
LanguageEnglish
Published United States American Society for Microbiology 01.01.2016
Subjects
Online AccessGet full text
ISSN1556-6811
1556-679X
DOI10.1128/CVI.00617-15

Cover

Abstract Enterotoxigenic Escherichia coli (ETEC) bacteria are the most common bacterial cause of diarrhea in children in resource-poor settings as well as in travelers. Although there are several approaches to develop an effective vaccine for ETEC, no licensed vaccines are currently available. A significant challenge to successful vaccine development is our poor understanding of the immune responses that correlate best with protection against ETEC illness. In this study, ETEC-specific mucosal immune responses were characterized and compared in subjects challenged with ETEC strain H10407 and in subjects rechallenged with the homologous organism. IgA responses to lipopolysaccharide (LPS), heat-labile toxin B subunit (LTB), and colonization factor antigen I (CFA/I) in antibody in lymphocyte supernatant (ALS), feces, lavage fluid, and saliva samples were evaluated. In all assay comparisons, ALS was the most sensitive indicator of a local immune response, but serum IgA was also a useful indirect marker of immune response to oral antigens. Volunteers challenged and then rechallenged with strain H10407 were protected from illness following rechallenge. Comparing mucosal antibody responses after primary and homologous rechallenge, protection against disease was reflected in reduced antibody responses to key ETEC antigens and in reduced fecal shedding of the H10407 challenge strain. Subjects challenged with strain H10407 mounted stronger antibody responses to LPS and LTB than subjects in the rechallenge group, while responses to CFA/I in the rechallenge group were higher than in the challenge group. We anticipate that this study will help provide an immunological benchmark for the evaluation of ETEC vaccines and immunization regimens in the future.
AbstractList Enterotoxigenic Escherichia coli (ETEC) bacteria are the most common bacterial cause of diarrhea in children in resource-poor settings as well as in travelers. Although there are several approaches to develop an effective vaccine for ETEC, no licensed vaccines are currently available. A significant challenge to successful vaccine development is our poor understanding of the immune responses that correlate best with protection against ETEC illness. In this study, ETEC-specific mucosal immune responses were characterized and compared in subjects challenged with ETEC strain H10407 and in subjects rechallenged with the homologous organism. IgA responses to lipopolysaccharide (LPS), heat-labile toxin B subunit (LTB), and colonization factor antigen I (CFA/I) in antibody in lymphocyte supernatant (ALS), feces, lavage fluid, and saliva samples were evaluated. In all assay comparisons, ALS was the most sensitive indicator of a local immune response, but serum IgA was also a useful indirect marker of immune response to oral antigens. Volunteers challenged and then rechallenged with strain H10407 were protected from illness following rechallenge. Comparing mucosal antibody responses after primary and homologous rechallenge, protection against disease was reflected in reduced antibody responses to key ETEC antigens and in reduced fecal shedding of the H10407 challenge strain. Subjects challenged with strain H10407 mounted stronger antibody responses to LPS and LTB than subjects in the rechallenge group, while responses to CFA/I in the rechallenge group were higher than in the challenge group. We anticipate that this study will help provide an immunological benchmark for the evaluation of ETEC vaccines and immunization regimens in the future.
Enterotoxigenic Escherichia coli (ETEC) bacteria are the most common bacterial cause of diarrhea in children in resource-poor settings as well as in travelers. Although there are several approaches to develop an effective vaccine for ETEC, no licensed vaccines are currently available. A significant challenge to successful vaccine development is our poor understanding of the immune responses that correlate best with protection against ETEC illness. In this study, ETEC-specific mucosal immune responses were characterized and compared in subjects challenged with ETEC strain H10407 and in subjects rechallenged with the homologous organism. IgA responses to lipopolysaccharide (LPS), heat-labile toxin B subunit (LTB), and colonization factor antigen I (CFA/I) in antibody in lymphocyte supernatant (ALS), feces, lavage fluid, and saliva samples were evaluated. In all assay comparisons, ALS was the most sensitive indicator of a local immune response, but serum IgA was also a useful indirect marker of immune response to oral antigens. Volunteers challenged and then rechallenged with strain H10407 were protected from illness following rechallenge. Comparing mucosal antibody responses after primary and homologous rechallenge, protection against disease was reflected in reduced antibody responses to key ETEC antigens and in reduced fecal shedding of the H10407 challenge strain. Subjects challenged with strain H10407 mounted stronger antibody responses to LPS and LTB than subjects in the rechallenge group, while responses to CFA/I in the rechallenge group were higher than in the challenge group. We anticipate that this study will help provide an immunological benchmark for the evaluation of ETEC vaccines and immunization regimens in the future.
Author Sack, David A.
DeNearing, Barbara
Bourgeois, A. Louis
Walker, Richard
Chakraborty, Subhra
Cage, Alicia
Ram, Malathi
Bauers, Nicole
Feller, Andrea
Harro, Clayton
Author_xml – sequence: 1
  givenname: Subhra
  surname: Chakraborty
  fullname: Chakraborty, Subhra
  organization: Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
– sequence: 2
  givenname: Clayton
  surname: Harro
  fullname: Harro, Clayton
  organization: Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
– sequence: 3
  givenname: Barbara
  surname: DeNearing
  fullname: DeNearing, Barbara
  organization: Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
– sequence: 4
  givenname: Malathi
  surname: Ram
  fullname: Ram, Malathi
  organization: Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
– sequence: 5
  givenname: Andrea
  surname: Feller
  fullname: Feller, Andrea
  organization: Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
– sequence: 6
  givenname: Alicia
  surname: Cage
  fullname: Cage, Alicia
  organization: Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
– sequence: 7
  givenname: Nicole
  surname: Bauers
  fullname: Bauers, Nicole
  organization: PATH, Washington, DC, USA
– sequence: 8
  givenname: A. Louis
  surname: Bourgeois
  fullname: Bourgeois, A. Louis
  organization: PATH, Washington, DC, USA
– sequence: 9
  givenname: Richard
  surname: Walker
  fullname: Walker, Richard
  organization: PATH, Washington, DC, USA
– sequence: 10
  givenname: David A.
  surname: Sack
  fullname: Sack, David A.
  organization: Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA
BackLink https://www.ncbi.nlm.nih.gov/pubmed/26581889$$D View this record in MEDLINE/PubMed
BookMark eNqNksuO0zAYhS00iLnAjjXykgUdfIvjsEAaVYVWmhGIy4id5Th2Y-TYndjh9p68D247UwFiwSqO_P3nHNvnFByFGAwAjzE6x5iI5_Pr1TlCHNczXN0DJ7iq-IzXzaeju7XA-BicpvQZIUa5qB-AY8IrgYVoTsDPea9GpbMZ3Q-VXQwwWng16ZiUh6thmIKB70zaxJBMgjnCRShszPGbW5vgNFwk3Zdh3TsFdfQOXiutXZm6CHmLJOgCVHA5DSrAYua9CWsDr2Jn_IuDNHw7Rut8sVC26JdfN6jxO1wFa_QulgodXMYh-riOUyqD-qD11eUevs-jKk5LjBiqH4L7VvlkHt1-z8DHV4sP8-Xs8s3r1fzicqYZrvNMmc5SoRvNWUtbxBvVYsGttZTgjiKiRasoJQRbViDLmopyjlHDaGOYIJaegZd73c3UDqbTJpQUXm726WVUTv65E1wv1_GLZDUuOlUReHorMMabyaQsB5e08V4FU44pcc0J5U3N_wtFgjMsSEGf_B7rkOfu2QvwbA_oMaY0GntAMJLbVsnSKrlrlcRba_IXrl3etWV76f7fQ78ALZ3UBg
CitedBy_id crossref_primary_10_1128_CVI_00276_17
crossref_primary_10_69833_RSVM_2024_1_44_02
crossref_primary_10_1016_j_lfs_2022_120660
crossref_primary_10_1371_journal_pntd_0006442
crossref_primary_10_1080_19490976_2020_1859813
crossref_primary_10_1093_infdis_jiy312
crossref_primary_10_1016_j_ebiom_2021_103308
crossref_primary_10_1080_19490976_2021_1891852
crossref_primary_10_3389_fmicb_2022_983403
crossref_primary_10_1101_cshperspect_a029546
crossref_primary_10_1038_s41541_020_00228_w
crossref_primary_10_3389_fpubh_2024_1332319
crossref_primary_10_3389_fmicb_2018_00440
crossref_primary_10_1080_21645515_2019_1578922
crossref_primary_10_3390_pharmaceutics14020239
crossref_primary_10_1016_j_vaccine_2019_01_003
crossref_primary_10_3389_fcimb_2021_705468
crossref_primary_10_1128_CVI_00082_16
crossref_primary_10_1371_journal_pone_0239888
crossref_primary_10_1038_s41577_021_00583_2
crossref_primary_10_1016_j_vaccine_2017_05_034
crossref_primary_10_1016_j_jim_2019_04_003
crossref_primary_10_3390_genes7120120
crossref_primary_10_1016_j_micinf_2019_02_007
crossref_primary_10_1080_21645515_2019_1575165
crossref_primary_10_1016_j_vaccine_2019_02_025
crossref_primary_10_3390_pathogens9090714
crossref_primary_10_3389_fimmu_2024_1446072
crossref_primary_10_1080_19490976_2020_1732852
Cites_doi 10.1093/oxfordjournals.aje.a115579
10.1128/iai.38.1.74-79.1982
10.1159/000233587
10.1016/0022-1759(88)90086-5
10.1093/oxfordjournals.aje.a112906
10.1371/journal.pone.0126863
10.1128/CDLI.11.6.1022-1027.2004
10.1016/j.vaccine.2011.06.084
10.1016/0264-410X(91)90130-X
10.1586/erv.12.37
10.1016/j.vaccine.2011.05.021
10.1016/j.bpg.2003.11.004
10.2310/7060.2005.12207
10.1016/S0264-410X(03)00077-X
10.1128/CVI.00391-08
10.1016/j.vaccine.2006.12.028
10.1016/S0264-410X(00)00056-6
10.1016/0264-410X(95)00102-7
10.1016/0264-410X(93)90002-F
10.1128/iai.56.2.387-394.1988
10.1097/QCO.0b013e32833dfca5
10.1586/14760584.2014.905745
10.1016/S0140-6736(82)91568-9
10.1186/1471-2458-13-S3-S11
10.1128/iai.23.3.729-736.1979
10.1146/annurev.immunol.23.021704.115723
10.1128/IAI.66.7.3311-3316.1998
10.1097/00006454-200204000-00012
10.1016/j.coi.2008.03.016
10.1128/CVI.05194-11
10.1128/CMR.18.3.465-483.2005
10.1093/infdis/153.3.527
10.1128/CVI.00364-12
10.1128/IAI.01021-09
ContentType Journal Article
Copyright Copyright © 2016, American Society for Microbiology. All Rights Reserved.
Copyright © 2016, American Society for Microbiology. All Rights Reserved. 2016 American Society for Microbiology
Copyright_xml – notice: Copyright © 2016, American Society for Microbiology. All Rights Reserved.
– notice: Copyright © 2016, American Society for Microbiology. All Rights Reserved. 2016 American Society for Microbiology
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7X8
7QL
7T5
C1K
H94
5PM
DOI 10.1128/CVI.00617-15
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
Bacteriology Abstracts (Microbiology B)
Immunology Abstracts
Environmental Sciences and Pollution Management
AIDS and Cancer Research Abstracts
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
AIDS and Cancer Research Abstracts
Immunology Abstracts
Bacteriology Abstracts (Microbiology B)
Environmental Sciences and Pollution Management
DatabaseTitleList
CrossRef
MEDLINE - Academic
MEDLINE
AIDS and Cancer Research Abstracts
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Biology
DocumentTitleAlternate Immune Responses to ETEC Challenge Model in Humans
EISSN 1556-679X
EndPage 64
ExternalDocumentID PMC4711095
26581889
10_1128_CVI_00617_15
Genre Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: PATH Vaccine Solutions
  grantid: 103904
GroupedDBID ---
.GJ
0R~
29B
2WC
39C
4.4
53G
5GY
5VS
AAFWJ
AAGFI
AAUOK
AAYXX
ADBBV
AENEX
AGVNZ
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BTFSW
C1A
CITATION
CS3
DIK
DU5
E3Z
EBS
EJD
F5P
GX1
H13
HYE
HZ~
KQ8
O9-
RHI
RNS
RPM
RSF
TR2
W2D
W8F
WOQ
CGR
CUY
CVF
ECM
EIF
NPM
RHF
UCJ
7X8
7QL
7T5
C1K
H94
5PM
ID FETCH-LOGICAL-c417t-aedf38c9c64b3b069ab186fff321d302c8ba33221f4c9cf495366109439e482f3
ISSN 1556-6811
IngestDate Thu Aug 21 14:00:53 EDT 2025
Thu Sep 04 22:34:05 EDT 2025
Fri Sep 05 06:58:07 EDT 2025
Thu Jan 02 23:10:33 EST 2025
Tue Jul 01 03:05:53 EDT 2025
Thu Apr 24 23:01:54 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License Copyright © 2016, American Society for Microbiology. All Rights Reserved.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c417t-aedf38c9c64b3b069ab186fff321d302c8ba33221f4c9cf495366109439e482f3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
Deceased.
Present address: Andrea Feller, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts, USA; A. Louis Bourgeois, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Citation Chakraborty S, Harro C, DeNearing B, Ram M, Feller A, Cage A, Bauers N, Bourgeois AL, Walker R, Sack DA. 2016. Characterization of mucosal immune responses to enterotoxigenic Escherichia coli vaccine antigens in a human challenge model: response profiles after primary infection and homologous rechallenge with strain H10407. Clin Vaccine Immunol 23:55–64. doi:10.1128/CVI.00617-15.
OpenAccessLink https://cvi.asm.org/content/cdli/23/1/55.full.pdf
PMID 26581889
PQID 1760864182
PQPubID 23479
PageCount 10
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_4711095
proquest_miscellaneous_1762369765
proquest_miscellaneous_1760864182
pubmed_primary_26581889
crossref_primary_10_1128_CVI_00617_15
crossref_citationtrail_10_1128_CVI_00617_15
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2016-01-01
PublicationDateYYYYMMDD 2016-01-01
PublicationDate_xml – month: 01
  year: 2016
  text: 2016-01-01
  day: 01
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: 1752 N St., N.W., Washington, DC
PublicationTitle Clinical and vaccine immunology
PublicationTitleAlternate Clin Vaccine Immunol
PublicationYear 2016
Publisher American Society for Microbiology
Publisher_xml – name: American Society for Microbiology
References e_1_3_2_26_2
e_1_3_2_27_2
e_1_3_2_28_2
e_1_3_2_29_2
e_1_3_2_20_2
Raqib R (e_1_3_2_32_2) 2004; 11
e_1_3_2_21_2
e_1_3_2_22_2
Levine MM (e_1_3_2_14_2) 1982; 33
e_1_3_2_24_2
e_1_3_2_25_2
Levine MM (e_1_3_2_23_2) 1980; 111
e_1_3_2_9_2
e_1_3_2_15_2
e_1_3_2_8_2
e_1_3_2_16_2
e_1_3_2_37_2
e_1_3_2_7_2
e_1_3_2_17_2
Wennerås C (e_1_3_2_3_2) 2004; 22
e_1_3_2_6_2
e_1_3_2_18_2
e_1_3_2_19_2
e_1_3_2_30_2
e_1_3_2_10_2
e_1_3_2_31_2
e_1_3_2_5_2
e_1_3_2_11_2
e_1_3_2_34_2
e_1_3_2_4_2
e_1_3_2_12_2
e_1_3_2_33_2
e_1_3_2_13_2
e_1_3_2_36_2
e_1_3_2_2_2
e_1_3_2_35_2
Svennerholm AM (e_1_3_2_38_2) 1982
6746103 - Int Arch Allergy Appl Immunol. 1984;75(1):38-43
6120313 - Lancet. 1982 Feb 6;1(8267):305-8
26020966 - PLoS One. 2015;10(5):e0126863
3512729 - J Infect Dis. 1986 Mar;153(3):527-34
12744870 - Vaccine. 2003 Jun 2;21(19-20):2394-403
3373004 - J Immunol Methods. 1988 May 25;110(1):85-91
21852546 - Clin Vaccine Immunol. 2011 Oct;18(10):1719-27
8438608 - Vaccine. 1993;11(2):100-6
20683261 - Curr Opin Infect Dis. 2010 Oct;23(5):481-7
6127806 - Scand J Infect Dis Suppl. 1982;33:83-95
3276624 - Infect Immun. 1988 Feb;56(2):387-94
10781858 - Vaccine. 2000 Jun 1;18(24):2704-12
16020685 - Clin Microbiol Rev. 2005 Jul;18(3):465-83
2157338 - Am J Epidemiol. 1990 May;131(5):886-904
15771575 - Annu Rev Immunol. 2005;23:367-86
6754618 - Infect Immun. 1982 Oct;38(1):74-9
15123079 - Best Pract Res Clin Gastroenterol. 2004 Apr;18(2):421-45
17224212 - Vaccine. 2007 Mar 30;25(14):2545-66
15539500 - Clin Diagn Lab Immunol. 2004 Nov;11(6):1022-7
22873126 - Expert Rev Vaccines. 2012 Jun;11(6):677-94
15996455 - J Travel Med. 2005 Mar-Apr;12(2):102-7
12075764 - Pediatr Infect Dis J. 2002 Apr;21(4):322-30
21616116 - Vaccine. 2011 Aug 11;29(35):5869-85
20086085 - Infect Immun. 2010 Apr;78(4):1750-9
23035175 - Clin Vaccine Immunol. 2012 Dec;19(12):1921-31
378834 - Infect Immun. 1979 Mar;23(3):729-36
1887674 - Vaccine. 1991 Jun;9(6):428-31
19193833 - Clin Vaccine Immunol. 2009 Apr;16(4):521-7
21723899 - Vaccine. 2011 Aug 26;29(37):6167-78
6987863 - Am J Epidemiol. 1980 Mar;111(3):347-55
8578831 - Vaccine. 1995 Nov;13(16):1488-94
24564510 - BMC Public Health. 2013;13 Suppl 3:S11
24702311 - Expert Rev Vaccines. 2014 May;13(5):631-9
18456483 - Curr Opin Immunol. 2008 Apr;20(2):162-9
15663170 - J Health Popul Nutr. 2004 Dec;22(4):370-82
9632600 - Infect Immun. 1998 Jul;66(7):3311-6
References_xml – ident: e_1_3_2_12_2
  doi: 10.1093/oxfordjournals.aje.a115579
– ident: e_1_3_2_16_2
  doi: 10.1128/iai.38.1.74-79.1982
– ident: e_1_3_2_31_2
  doi: 10.1159/000233587
– ident: e_1_3_2_37_2
  doi: 10.1016/0022-1759(88)90086-5
– volume: 111
  start-page: 347
  year: 1980
  ident: e_1_3_2_23_2
  article-title: Lack of person-to-person transmission of enterotoxigenic Escherichia coli despite close contact
  publication-title: Am J Epidemiol
  doi: 10.1093/oxfordjournals.aje.a112906
– ident: e_1_3_2_36_2
  doi: 10.1371/journal.pone.0126863
– volume: 11
  start-page: 1022
  year: 2004
  ident: e_1_3_2_32_2
  article-title: Use of antibodies in lymphocyte secretions for detection of subclinical tuberculosis infection in asymptomatic contacts
  publication-title: Clin Diagn Lab Immunol
  doi: 10.1128/CDLI.11.6.1022-1027.2004
– ident: e_1_3_2_4_2
  doi: 10.1016/j.vaccine.2011.06.084
– ident: e_1_3_2_26_2
  doi: 10.1016/0264-410X(91)90130-X
– ident: e_1_3_2_9_2
  doi: 10.1586/erv.12.37
– ident: e_1_3_2_22_2
  doi: 10.1016/j.vaccine.2011.05.021
– ident: e_1_3_2_17_2
  doi: 10.1016/j.bpg.2003.11.004
– ident: e_1_3_2_2_2
  doi: 10.2310/7060.2005.12207
– ident: e_1_3_2_27_2
  doi: 10.1016/S0264-410X(03)00077-X
– ident: e_1_3_2_35_2
  doi: 10.1128/CVI.00391-08
– volume: 33
  start-page: 83
  year: 1982
  ident: e_1_3_2_14_2
  article-title: Reactogenicity, immunogenicity and efficacy studies of Escherichia coli type 1 somatic pili parenteral vaccine in man
  publication-title: Scand J Infect Dis Suppl
– ident: e_1_3_2_18_2
  doi: 10.1016/j.vaccine.2006.12.028
– ident: e_1_3_2_21_2
  doi: 10.1016/S0264-410X(00)00056-6
– ident: e_1_3_2_29_2
  doi: 10.1016/0264-410X(95)00102-7
– ident: e_1_3_2_5_2
– ident: e_1_3_2_11_2
  doi: 10.1016/0264-410X(93)90002-F
– ident: e_1_3_2_15_2
  doi: 10.1128/iai.56.2.387-394.1988
– ident: e_1_3_2_8_2
  doi: 10.1097/QCO.0b013e32833dfca5
– ident: e_1_3_2_10_2
  doi: 10.1586/14760584.2014.905745
– start-page: 305
  year: 1982
  ident: e_1_3_2_38_2
  article-title: Intestinal antibody responses after immunisation with cholera B subunit
  publication-title: Lancet
  doi: 10.1016/S0140-6736(82)91568-9
– ident: e_1_3_2_6_2
  doi: 10.1186/1471-2458-13-S3-S11
– ident: e_1_3_2_13_2
  doi: 10.1128/iai.23.3.729-736.1979
– ident: e_1_3_2_33_2
  doi: 10.1146/annurev.immunol.23.021704.115723
– ident: e_1_3_2_25_2
  doi: 10.1128/IAI.66.7.3311-3316.1998
– volume: 22
  start-page: 370
  year: 2004
  ident: e_1_3_2_3_2
  article-title: Prevalence of enterotoxigenic Escherichia coli-associated diarrhoea and carrier state in the developing world
  publication-title: J Health Popul Nutr
– ident: e_1_3_2_30_2
  doi: 10.1097/00006454-200204000-00012
– ident: e_1_3_2_34_2
  doi: 10.1016/j.coi.2008.03.016
– ident: e_1_3_2_20_2
  doi: 10.1128/CVI.05194-11
– ident: e_1_3_2_7_2
  doi: 10.1128/CMR.18.3.465-483.2005
– ident: e_1_3_2_19_2
  doi: 10.1093/infdis/153.3.527
– ident: e_1_3_2_24_2
  doi: 10.1128/CVI.00364-12
– ident: e_1_3_2_28_2
  doi: 10.1128/IAI.01021-09
– reference: 15539500 - Clin Diagn Lab Immunol. 2004 Nov;11(6):1022-7
– reference: 24564510 - BMC Public Health. 2013;13 Suppl 3:S11
– reference: 8438608 - Vaccine. 1993;11(2):100-6
– reference: 15771575 - Annu Rev Immunol. 2005;23:367-86
– reference: 24702311 - Expert Rev Vaccines. 2014 May;13(5):631-9
– reference: 12075764 - Pediatr Infect Dis J. 2002 Apr;21(4):322-30
– reference: 12744870 - Vaccine. 2003 Jun 2;21(19-20):2394-403
– reference: 20683261 - Curr Opin Infect Dis. 2010 Oct;23(5):481-7
– reference: 378834 - Infect Immun. 1979 Mar;23(3):729-36
– reference: 15123079 - Best Pract Res Clin Gastroenterol. 2004 Apr;18(2):421-45
– reference: 6746103 - Int Arch Allergy Appl Immunol. 1984;75(1):38-43
– reference: 8578831 - Vaccine. 1995 Nov;13(16):1488-94
– reference: 17224212 - Vaccine. 2007 Mar 30;25(14):2545-66
– reference: 2157338 - Am J Epidemiol. 1990 May;131(5):886-904
– reference: 1887674 - Vaccine. 1991 Jun;9(6):428-31
– reference: 15996455 - J Travel Med. 2005 Mar-Apr;12(2):102-7
– reference: 16020685 - Clin Microbiol Rev. 2005 Jul;18(3):465-83
– reference: 15663170 - J Health Popul Nutr. 2004 Dec;22(4):370-82
– reference: 3512729 - J Infect Dis. 1986 Mar;153(3):527-34
– reference: 21616116 - Vaccine. 2011 Aug 11;29(35):5869-85
– reference: 22873126 - Expert Rev Vaccines. 2012 Jun;11(6):677-94
– reference: 19193833 - Clin Vaccine Immunol. 2009 Apr;16(4):521-7
– reference: 3373004 - J Immunol Methods. 1988 May 25;110(1):85-91
– reference: 6754618 - Infect Immun. 1982 Oct;38(1):74-9
– reference: 10781858 - Vaccine. 2000 Jun 1;18(24):2704-12
– reference: 26020966 - PLoS One. 2015;10(5):e0126863
– reference: 6120313 - Lancet. 1982 Feb 6;1(8267):305-8
– reference: 6127806 - Scand J Infect Dis Suppl. 1982;33:83-95
– reference: 18456483 - Curr Opin Immunol. 2008 Apr;20(2):162-9
– reference: 23035175 - Clin Vaccine Immunol. 2012 Dec;19(12):1921-31
– reference: 6987863 - Am J Epidemiol. 1980 Mar;111(3):347-55
– reference: 21723899 - Vaccine. 2011 Aug 26;29(37):6167-78
– reference: 9632600 - Infect Immun. 1998 Jul;66(7):3311-6
– reference: 20086085 - Infect Immun. 2010 Apr;78(4):1750-9
– reference: 21852546 - Clin Vaccine Immunol. 2011 Oct;18(10):1719-27
– reference: 3276624 - Infect Immun. 1988 Feb;56(2):387-94
SSID ssj0043687
Score 2.2944028
Snippet Enterotoxigenic Escherichia coli (ETEC) bacteria are the most common bacterial cause of diarrhea in children in resource-poor settings as well as in travelers....
Enterotoxigenic Escherichia coli (ETEC) bacteria are the most common bacterial cause of diarrhea in children in resource-poor settings as well as in travelers....
SourceID pubmedcentral
proquest
pubmed
crossref
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 55
SubjectTerms Antibodies, Bacterial - blood
Antibody Formation
Antigens, Bacterial - immunology
Diarrhea - immunology
Diarrhea - microbiology
Diarrhea - prevention & control
Enterotoxigenic Escherichia coli - chemistry
Enterotoxigenic Escherichia coli - immunology
Enterotoxigenic Escherichia coli - pathogenicity
Escherichia coli
Escherichia coli Infections - immunology
Escherichia coli Infections - microbiology
Escherichia coli Infections - prevention & control
Escherichia coli Proteins - immunology
Escherichia coli Vaccines - administration & dosage
Escherichia coli Vaccines - immunology
Feces - microbiology
Fimbriae Proteins - immunology
Humans
Immunity, Mucosal
Immunoglobulin A - blood
Saliva - immunology
Spotlight
Vaccines
Title Characterization of Mucosal Immune Responses to Enterotoxigenic Escherichia coli Vaccine Antigens in a Human Challenge Model: Response Profiles after Primary Infection and Homologous Rechallenge with Strain H10407
URI https://www.ncbi.nlm.nih.gov/pubmed/26581889
https://www.proquest.com/docview/1760864182
https://www.proquest.com/docview/1762369765
https://pubmed.ncbi.nlm.nih.gov/PMC4711095
Volume 23
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ta9RAEF5qRRFBtL6db4ygn47UZPO25zc5K1fhimBb-i1s3mjgTOSaE9v_6f9xZnezyV2rVL-EI7fZZDNPdmZ2n5lh7I3r57mHisGRWZw5QSwCZyJRIGj8Su4HQZlLWu-YH0Szo-DzSXiydePugLW0atPd7OLKuJL_kSqeQ7lSlOw_SNZ2iifwN8oXjyhhPF5LxlObbfnCWn5zoqBTAg0K_KCiDIoDqxM5KAZA0zY_KQVnlY33zkhkFdGdxwiIanwsM9pop5QC1ERxZaVZ6J92ZVdU_bSFZtLpzincgBI8nZmS419MCot9w_TShOdZ841mWuLcorFqe1MrwV9VqYrxDN02XZ7WZk_oIjephx_m8Soa29p-gGEnoC-huWur9HQp-9l1qaN5pgt53va8g4_FAX7npqiL2Xjp9730WrFcED1zuDbiDddGzHQeRk4kzHReDM7FqoCv1QE65nkN63pC1zmEjWmg861fVjqcAimmx_u7yiB0vLBXrh2hYEPnWiak8sG4SPDqRF2dUMaEmzyOFelArT1pu4JKBahSQd2YujAOLt4N771uYF3ymjbJvwNr6vA-u2fcIPigMf2AbRX1DrulC6Oe77Dbc0P5eMh-bYIcmhIMyEGDHCzIoW1gA-QwADkQyMGAHDqQQ1WDBAVysCAHBfL3tmvoIA4K4mAgDhbigACFHuIwgDgQxEFDHDTEH7GjT3uH05ljapE4WeDFrSOLvPRFNsmiIPVTN5rI1BNRWZY-93Lf5ZlIpY_K0SsDbFQSazuiSgZo7xeB4KX_mG3XTV08ZZCW6BV5JRdhjiakm6ZxGEs_JMIhlXfzR2zcCTDJTKJ-esJFchVYRuytbf1dD_0P7V53WEhQg9C2oKwLfB-JF0euiAJP8L-24X6Ergv280Tjx96NoxPjCTEZsXgNWbYBZbBf_6euTlUme7SM8R2Fz645hufsTv-Vv2Db7XJVvESfoE1fqU_lNy4MFL8
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Characterization+of+Mucosal+Immune+Responses+to+Enterotoxigenic+Escherichia+coli+Vaccine+Antigens+in+a+Human+Challenge+Model%3A+Response+Profiles+after+Primary+Infection+and+Homologous+Rechallenge+with+Strain+H10407&rft.jtitle=Clinical+and+vaccine+immunology&rft.au=Chakraborty%2C+Subhra&rft.au=Harro%2C+Clayton&rft.au=DeNearing%2C+Barbara&rft.au=Ram%2C+Malathi&rft.date=2016-01-01&rft.issn=1556-6811&rft.eissn=1556-679X&rft.volume=23&rft.issue=1&rft.spage=55&rft.epage=64&rft_id=info:doi/10.1128%2FCVI.00617-15&rft.externalDBID=n%2Fa&rft.externalDocID=10_1128_CVI_00617_15
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1556-6811&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1556-6811&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1556-6811&client=summon